Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Published:2015-10 Issue:13 Volume:16 Page:1344-1354
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bruix Jordi,Takayama Tadatoshi,Mazzaferro Vincenzo,Chau Gar-Yang,Yang Jiamei,Kudo Masatoshi,Cai Jianqiang,Poon Ronnie T,Han Kwang-Hyub,Tak Won Young,Lee Han Chu,Song Tianqiang,Roayaie Sasan,Bolondi Luigi,Lee Kwan Sik,Makuuchi Masatoshi,Souza Fabricio,Berre Marie-Aude Le,Meinhardt Gerold,Llovet Josep M

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

2. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

3. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;J Hepatol,2012

5. Risk factors of hepatocellular carcinoma--current status and perspectives;Gao;Asian Pac J Cancer Prev,2012

Cited by 780 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape;Cancers;2024-02-04

2. Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives;Hepatobiliary Surgery and Nutrition;2024-02

3. Grading severity of microscopic vascular invasion was independently associated with recurrence and survival following hepatectomy for solitary hepatocellular carcinoma;Hepatobiliary Surgery and Nutrition;2024-02

4. IMbrave050 Study: A Revolutionary Breakthrough in Hepatocellular Carcinoma Adjuvant Therapy;Journal of Clinical and Experimental Hepatology;2024-02

5. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial;Nature Medicine;2024-01-19